Novartis AG

NOVN

CH0012005267

Pharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 04:08:29 2026-06-30 am EDT			5-day change	1st Jan Change
127.48 ^CHF	+1.01%		+3.37%	+16.41%

Jun. 29	Swiss stocks - Factors to watch on June 29	RE
Jun. 26	Swiss pharma at risk of US trade investigation, industry body says	RE

Health Care Down as Traders Rotate to Other Defensive Areas -- Health Care Roundup

Published on 03/27/2026 at 05:37 pm EDT

Dow Jones

NOVARTIS AG

+1.03%

ASTRAZENECA PLC

+1.04%

Health-care companies fell sharply as traders rotated out of the sector into other defensive areas such as utilities.

Novartis said it agreed to buy biotech company Excellergy for up to $2 billion, adding a new approach to treat allergic diseases to its immunology pipeline.

AstraZeneca said a lung-disease drug candidate met the primary goal in two late-stage clinical trials, reducing the rate at which patients' symptoms worsened.

The Justice Department filed an antitrust lawsuit against the prominent hospital system NewYork-Presbyterian, alleging that it used restrictions in its contracts with insurers to limit price competition and block lower-cost healthcare options.

Write to Rob Curran at rob.curran@dowjones.com

(END) Dow Jones Newswires

03-27-26 1736ET

Stocks mentioned in the article

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Off-Hours Price	Change	5-day change	Capi.
	NOVARTIS AG	127.50CHF	+1.03%	+3.34%	286B
	ASTRAZENECA PLC	14,446.00GBX	+1.04%	+6.39%	294B

Latest news about Novartis AG

Jun. 29	Swiss stocks - Factors to watch on June 29	RE
Jun. 26	Swiss pharma at risk of US trade investigation, industry body says	RE
Jun. 26	Swiss Market Index Snaps Gains; ABB Shares Down	MT
Jun. 26	Novartis Europharm Wins European Medicines Agency's Positive Opinion for Hypercholesterolemia Drug	MT
Jun. 25	NOVARTIS AG : Deutsche Bank maintains a Buy rating	ZD
Jun. 25	US prices for new drugs fell in 2025 as fewer costly gene therapies were launched	RE
Jun. 24	European Stocks Close Mixed; Oil Prices Tumble as Hormuz Traffic Rises	MT
Jun. 24	GSK launches tender offer for USD10.6 billion purchase of Nuvalent	AN
Jun. 24	Novartis, Antares Therapeutics Sign Oncology Drug Discovery Deal Worth Up to $1.9 Billion	MT
Jun. 24	Antares Therapeutics, Inc. and Novartis Enter Agreement to Discover, Develop and Commercialize First-In-Class Cancer Therapies	CI
Jun. 24	Antares Therapeutics signs potential $1.9 billion cancer drug deal with Novartis	RE
Jun. 24	Becoming Rentable and Novartis Join Smashing My Limits and Going Places Campaign to Expand Accessible Lodging for People Living with Sma	CI
Jun. 23	Sanofi Multiple Sclerosis Drug Gets EU Approval -- Update	DJ
Jun. 22	Nuvectis gains two experimental drugs in licensing deal with China's Haisco	RE
Jun. 22	Storebrand Europa rose 2.89 percent in May, AI optimism boosted market performance	FW

Chart Novartis AG

Duration

Period

NOVN: Dynamic Chart

Company Profile

Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by therapeutic area as follows: - oncology (30.9%); - immunology (18.9%); - cardiovascular, renal and metabolic diseases (16.4%); - neuroscience (11%). The remaining net sales (22.8%) are from contract manufacturing of pharmaceutical products. At the end of 2025, Novartis AG had over 31 production sites worldwide. Net sales are distributed geographically as follows: Switzerland (2.6%), Europe (28.1%), the United States (42.8%), Asia/Africa/Australasia (19.8%), Canada and Latin America (6.7%).

Employees

75,267

Sector

Pharmaceuticals

Calendar

Earnings release - Q2 2026

More about the company